Patents
 

Next-generation therapies in lung cancer

Paul HOFMAN, Professor-Clinician, PU-PHCE
 
  • SQSTM1 and its use in cancer therapy

    Nathalie YAZBECK, Amine BELAID, Grégoire D’ANDREA, Iris GROSJEAN, Paul HOFMAN, Baharia MOGRABI
    2021
    EP20306577.6

  • Method for identifying gene products involved in incomplete response of drug sensitive cell populations

    Jérémie Roux Agnès Paquet Mickael Meyer Luis Pereira
    2021
    WO2021058503A1

  • Process for multi-analyses of rare cells extracted or isolated from biological samples through filtration

    Sophie LAGET, Patrizia Paterlini-Brechot, Paul Hofman, Thierry CAPIOD
    2020
    EP3351935B1

    2013  CA US RU CN EP WO JP EP BR RU CA MX ES CN AU EP 2014  IL 2015  HK 2018  AU JP 2020  US

  • P2rx7 modulators in therapy

    Valérie Vouret Laetitia Douguet Alina Ghinet Germain Homerin Benoît Guy Marie Rigo Davy Jérémy Baudelet Xavier Dezitter Régis Millet Christophe Furman
    2019
    WO2019185868A1

  • Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma

    Brest P (Co-PI), Lassalle S, Zangari J, Mari B, Hofman P(Co-PI)

    PCT/EP2017/052168

  • Tumoral Deconvolution

    Malot C, Brest P

    PCT/EP2017/058983

  • Methods for diagnosing and treating a pathology associated with a synonymous mutation occurring within a gene of interest.

     Principal inventors: Brest P (PI),. P. Hofman, B. Mograbi

    WO2011045349A3.

     

  • Method for determining the efficiency of a cancer treatment

    Patrick Brest, Paul Hofman, Baharia Mograbi

    Patent ID: WO 2011067346 A1

Research teams